General MedicationsORALGeneric

ATAZANAVIR SULFATE; RITONAVIR

Standard Dose

300MG; 100MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: PRIORITY Marketing status: None (Tentative Approval)

Summary

Approval overview ATAZANAVIR SULFATE; RITONAVIR is listed in Drugs@FDA under application 205508 (NDA).

Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient ATAZANAVIR SULFATE; RITONAVIR Form and strength TABLET; ORAL - 300MG; 100MG Sponsor EMCURE PHARMS LTD Submission history Latest submission status date: 2014-03-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview ATAZANAVIR SULFATE; RITONAVIR is listed in Drugs@FDA under application 205508 (NDA). Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient ATAZANAVIR SULFATE; RITONAVIR Form and strength TABLET; ORAL - 300MG; 100MG Sponsor EMCURE PHARMS LTD Submission history Latest submission status date: 2014-03-17 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: PRIORITY

Interaction Notes

No interaction notes stored yet.